These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The future of type 1 cannabinoid receptor allosteric ligands. Alaverdashvili M; Laprairie RB Drug Metab Rev; 2018 Feb; 50(1):14-25. PubMed ID: 29355038 [TBL] [Abstract][Full Text] [Related]
8. Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities. Hryhorowicz S; Kaczmarek-Ryś M; Andrzejewska A; Staszak K; Hryhorowicz M; Korcz A; Słomski R Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771126 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. Garai S; Schaffer PC; Laprairie RB; Janero DR; Pertwee RG; Straiker A; Thakur GA Bioorg Med Chem; 2021 Nov; 50():116421. PubMed ID: 34634617 [TBL] [Abstract][Full Text] [Related]
10. Allosteric Modulation of the CB1 Cannabinoid Receptor by Cannabidiol-A Molecular Modeling Study of the N-Terminal Domain and the Allosteric-Orthosteric Coupling. Jakowiecki J; Abel R; Orzeł U; Pasznik P; Preissner R; Filipek S Molecules; 2021 Apr; 26(9):. PubMed ID: 33922473 [TBL] [Abstract][Full Text] [Related]
11. Assessing Allosteric Modulation of CB Scott CE; Kendall DA Methods Enzymol; 2017; 593():317-342. PubMed ID: 28750809 [TBL] [Abstract][Full Text] [Related]
12. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains. Janero DR; Korde A; Makriyannis A Methods Enzymol; 2017; 593():217-235. PubMed ID: 28750804 [TBL] [Abstract][Full Text] [Related]
13. Approaches to Assess Biased Signaling at the CB1R Receptor. Laprairie RB; Stahl EL; Bohn LM Methods Enzymol; 2017; 593():259-279. PubMed ID: 28750807 [TBL] [Abstract][Full Text] [Related]
14. Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor. Nguyen T; Li JX; Thomas BF; Wiley JL; Kenakin TP; Zhang Y Med Res Rev; 2017 May; 37(3):441-474. PubMed ID: 27879006 [TBL] [Abstract][Full Text] [Related]
15. Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities. Khurana L; Mackie K; Piomelli D; Kendall DA Neuropharmacology; 2017 Sep; 124():3-12. PubMed ID: 28527758 [TBL] [Abstract][Full Text] [Related]
16. Translational potential of allosteric modulators targeting the cannabinoid CB Lu D; Immadi SS; Wu Z; Kendall DA Acta Pharmacol Sin; 2019 Mar; 40(3):324-335. PubMed ID: 30333554 [TBL] [Abstract][Full Text] [Related]
17. Tuning the endocannabinoid system: allosteric modulators of the CB1 receptor. Ross RA Br J Pharmacol; 2007 Nov; 152(5):565-6. PubMed ID: 17592508 [TBL] [Abstract][Full Text] [Related]
18. Multiple Binding Sites Contribute to the Mechanism of Mixed Agonistic and Positive Allosteric Modulators of the Cannabinoid CB1 Receptor. Saleh N; Hucke O; Kramer G; Schmidt E; Montel F; Lipinski R; Ferger B; Clark T; Hildebrand PW; Tautermann CS Angew Chem Int Ed Engl; 2018 Mar; 57(10):2580-2585. PubMed ID: 29314474 [TBL] [Abstract][Full Text] [Related]
19. Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists. Janero DR Expert Opin Emerg Drugs; 2012 Mar; 17(1):17-29. PubMed ID: 22335400 [TBL] [Abstract][Full Text] [Related]
20. Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor. Bertini S; Chicca A; Gado F; Arena C; Nieri D; Digiacomo M; Saccomanni G; Zhao P; Abood ME; Macchia M; Gertsch J; Manera C Bioorg Med Chem; 2017 Dec; 25(24):6427-6434. PubMed ID: 29079014 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]